Treatment of portal systemic encephalopathy: standard and new treatments

Rev Invest Clin. 1990 Jul:42 Suppl:141-8.

Abstract

The management of hepatic encephalopathy should be considered accordingly with the precipitating factor and the type of encephalopathy. Ideally the therapeutic approach must be useful for both acute and chronic forms of encephalopathy. Current treatment of hepatic encephalopathy consists of certain well-established measures attempting to identify and treat the precipitating factors, and to reduce the intestinal nitrogenous compounds formation and absorption by dietary restriction or bowel-cleansing with catartics or antibiotics such as neomycin, metronidazol, etc. This review describes briefly several therapeutic modalities.

Publication types

  • Review

MeSH terms

  • Bromocriptine / therapeutic use
  • Clinical Trials as Topic
  • Colon / microbiology
  • Dietary Proteins / adverse effects
  • Disaccharides / therapeutic use
  • Double-Blind Method
  • Enema
  • GABA Antagonists / therapeutic use
  • Gastrointestinal Hemorrhage / complications
  • Hepatic Encephalopathy / diet therapy
  • Hepatic Encephalopathy / drug therapy
  • Hepatic Encephalopathy / etiology
  • Hepatic Encephalopathy / therapy*
  • Humans
  • Hyperammonemia / complications
  • Laxatives / therapeutic use
  • Levodopa / therapeutic use
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / diet therapy
  • Malnutrition / complications
  • Metabolic Networks and Pathways
  • Plant Proteins, Dietary / therapeutic use
  • Sodium Benzoate / therapeutic use
  • Zinc / therapeutic use

Substances

  • Dietary Proteins
  • Disaccharides
  • GABA Antagonists
  • Laxatives
  • Plant Proteins, Dietary
  • Bromocriptine
  • Levodopa
  • Zinc
  • Sodium Benzoate